Christopher Pierce's Insider Trades & SAST Disclosures
Christopher Pierce's most recent trade in Prelude Therapeutics Inc was a trade of 17,000 Employee Stock Option (right to buy) done . Disclosure was reported to the exchange on Sept. 2, 2021.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Christopher Pierce.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Prelude Therapeutics Inc | Christopher Pierce | EVP and Chief of Business Oper | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Sep 2021 | 17,000 | 207,796 | - | - | Employee Stock Option (right to buy) | |
| Prelude Therapeutics Inc | Christopher Pierce | EVP and Chief of Business Oper | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.85 per share. | 02 Sep 2021 | 17,000 | 20,750 | - | 12.9 | 218,450 | Common Stock |
| Prelude Therapeutics Inc | Christopher Pierce | EVP and Chief of Business Oper | Sale of securities on an exchange or to another person at price $ 42.50 per share. | 02 Sep 2021 | 6,930 | 3,750 | - | 42.5 | 294,507 | Common Stock |
| Prelude Therapeutics Inc | Christopher Pierce | EVP and Chief of Business Oper | Sale of securities on an exchange or to another person at price $ 41.52 per share. | 02 Sep 2021 | 6,727 | 10,680 | - | 41.5 | 279,289 | Common Stock |
| Prelude Therapeutics Inc | Christopher Pierce | EVP and Chief of Business Oper | Sale of securities on an exchange or to another person at price $ 40.29 per share. | 02 Sep 2021 | 3,343 | 17,407 | - | 40.3 | 134,697 | Common Stock |
| Prelude Therapeutics Inc | Christopher Pierce | EVP and Chief of Business Oper | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jul 2021 | 85,000 | 85,000 | - | - | Employee Stock Option (Right to Buy) | |
| Prelude Therapeutics Inc | Christopher Pierce | EVP and Chief of Business Oper | Sale of securities on an exchange or to another person at price $ 40.29 per share. | 29 Apr 2021 | 3,295 | 3,750 | - | 40.3 | 132,765 | Common Stock |
| Prelude Therapeutics Inc | Christopher Pierce | EVP and Chief of Business Oper | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Apr 2021 | 3,295 | 4,323 | - | - | Employee Stock Option (right to buy) | |
| Prelude Therapeutics Inc | Christopher Pierce | EVP and Chief of Business Oper | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.89 per share. | 29 Apr 2021 | 3,295 | 7,045 | - | 1.9 | 6,228 | Common Stock |
| Prelude Therapeutics Inc | Christopher Pierce | EVP and Chief of Business Oper | Grant, award, or other acquisition of securities at price $ 1.89 per share. | 08 Apr 2021 | 200 | 3,950 | - | 1.9 | 378 | Common Stock |
| Prelude Therapeutics Inc | Christopher Pierce | EVP and Chief of Business Oper | Sale of securities on an exchange or to another person at price $ 40.00 per share. | 08 Apr 2021 | 200 | 3,750 | - | 40 | 8,000 | Common Stock |
| Prelude Therapeutics Inc | Christopher Pierce | EVP and Chief of Business Oper | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Apr 2021 | 200 | 7,618 | - | - | Employee Stock Option (right to buy) | |
| Prelude Therapeutics Inc | Christopher Pierce | EVP and Chief of Business Oper | Grant, award, or other acquisition of securities at price $ 1.89 per share. | 07 Apr 2021 | 828 | 4,578 | - | 1.9 | 1,565 | Common Stock |
| Prelude Therapeutics Inc | Christopher Pierce | EVP and Chief of Business Oper | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Apr 2021 | 828 | 7,818 | - | - | Employee Stock Option (right to buy) | |
| Prelude Therapeutics Inc | Christopher Pierce | EVP and Chief of Business Oper | Sale of securities on an exchange or to another person at price $ 40.08 per share. | 07 Apr 2021 | 828 | 3,750 | - | 40.1 | 33,188 | Common Stock |
| Prelude Therapeutics Inc | Christopher Pierce | EVP and Chief of Business Oper | Purchase of securities on an exchange or from another person at price $ 19.00 per share. | 29 Sep 2020 | 3,750 | 3,750 | - | 19 | 71,250 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges